These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 14795905)

  • 1. Multiple sclerosis studies in the United States and Canada.
    KURLAND LT; BOWMAN M; BRADFORD C; BURNS CM; CAMPBELL CS
    Manit Med Rev; 1950 Dec; 30(10):700-2. PubMed ID: 14795905
    [No Abstract]   [Full Text] [Related]  

  • 2. Multiple sclerosis morbidity and mortality studies in the United States and Canada.
    KURLAND LT
    Trans Am Neurol Assoc; 1950; 51():264-7. PubMed ID: 14788131
    [No Abstract]   [Full Text] [Related]  

  • 3. The frequency and geographic distribution of multiple sclerosis as indicated by mortality statistics and morbidity surveys in the United States and Canada.
    KURLAND LT
    Am J Hyg; 1952 May; 55(3):457-81. PubMed ID: 14933384
    [No Abstract]   [Full Text] [Related]  

  • 4. GEOGRAPHIC AND CLIMATIC ASPECTS OF MULTIPLE SCLEROSIS; A REVIEW OF CURRENT HYPOTHESES.
    KURLAND LT; REED D
    Am J Public Health Nations Health; 1964 Apr; 54(4):588-97. PubMed ID: 14136323
    [No Abstract]   [Full Text] [Related]  

  • 5. Multiple sclerosis. A clinical and theoretical review.
    Rose AS
    J Neurosurg; 1974 Sep; 41(3):279-84. PubMed ID: 4606824
    [No Abstract]   [Full Text] [Related]  

  • 6. Registry studies of long-term multiple sclerosis outcomes: description of key registries.
    Hurwitz BJ
    Neurology; 2011 Jan; 76(1 Suppl 1):S3-6. PubMed ID: 21205680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of current multiple sclerosis registries.
    Hurwitz BJ
    Neurology; 2011 Jan; 76(1 Suppl 1):S7-13. PubMed ID: 21205683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of multiple sclerosis using recombinant interferon-beta].
    Polman CH; Barkhof F; van Loenen AC; Lucas CJ; Koetsier JC
    Ned Tijdschr Geneeskd; 1994 Jan; 138(1):7-10. PubMed ID: 8289963
    [No Abstract]   [Full Text] [Related]  

  • 9. World-wide trends in multiple sclerosis mortality.
    Lai SM; Zhang ZX; Alter M; Sobel E
    Neuroepidemiology; 1989; 8(2):56-67. PubMed ID: 2922099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bibliometric profile of the global scientific research on multiple sclerosis (2003-2012).
    Aleixandre-Benavent R; Alonso-Arroyo A; González de Dios J; Vidal-Infer A; González-Muñoz M; Sempere ÁP
    Mult Scler; 2015 Feb; 21(2):235-45. PubMed ID: 25257610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The geographic distribution of multiple sclerosis and its estimated prevalence in the United States.
    LIMBURG CC
    Res Publ Assoc Res Nerv Ment Dis; 1950; 28():15-24. PubMed ID: 15413001
    [No Abstract]   [Full Text] [Related]  

  • 12. An overview of biosimilars and non-biologic complex drugs in Europe, the United States, and Canada and their relevance to multiple sclerosis.
    Gran-Ruaz S; Mani A; O'Quinn S
    Mult Scler; 2017 Dec; 23(14):1824-1829. PubMed ID: 29095099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unintended consequences.
    Nat Immunol; 2002 Jan; 3(1):1. PubMed ID: 11753395
    [No Abstract]   [Full Text] [Related]  

  • 14. [The study of multiple sclerosis in the U.S].
    STEINER G
    Nervenarzt; 1950 Nov; 21(11):494-9. PubMed ID: 14796788
    [No Abstract]   [Full Text] [Related]  

  • 15. Predicting the use of occupational therapy services among people with multiple sclerosis in Atlantic Canada.
    Finlayson M; DalMonte J
    Can J Occup Ther; 2002 Oct; 69(4):239-48. PubMed ID: 12395625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Editorial regarding "Explaining multiple sclerosis prevalence by ultraviolet exposure: a geospatial analysis," by Beretich and Beretich.
    Ebers GC
    Mult Scler; 2009 Aug; 15(8):889-90. PubMed ID: 19667016
    [No Abstract]   [Full Text] [Related]  

  • 17. Results of an international questionnaire on immunosuppressive treatment of multiple sclerosis.
    Hommes OR; Weiner HL
    Mult Scler; 2002 Apr; 8(2):139-41. PubMed ID: 11990871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Highlights From the 2014 Joint Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)-European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).
    Costello FE; Santos-Lang M
    J Neuroophthalmol; 2015 Jun; 35(2):e15-6. PubMed ID: 25768247
    [No Abstract]   [Full Text] [Related]  

  • 19. MS specialist nursing in North America.
    J Adv Nurs; 2001 Oct; 36(1):7. PubMed ID: 11601412
    [No Abstract]   [Full Text] [Related]  

  • 20. Key players in neurodegenerative disorders in focus-New insights into the proteomic profile of Alzheimer's disease, schizophrenia, ALS, and multiple sclerosis-24th HUPO BPP Workshop: September 29, 2015, Vancouver, Canada.
    Schrötter A; Park YM; Marcus K; Martins-de-Souza D; Nilsson P; Magraoui FE; Meyer HE; Grinberg LT
    Proteomics; 2016 Apr; 16(7):1047-50. PubMed ID: 26872682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.